EMA Guideline Seeks To Revive Drug Development For Alzheimer's Disease
This article was originally published in SRA
Executive Summary
The European Medicines Agency is seeking feedback on a revised guideline on developing drugs for treating Alzheimer’s disease, a condition for which the agency has warned there is a lack of medicines innovation.